Andere Sprachen Cerus Corporation

Aktien

905249

US1570851014

CERS

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 25.04.2024			% 5 Tage	% 1. Jan.
1.7 ^USD	+2.41%		+3.66%	-21.30%

12.04.	CERUS CORPORATION : Craig-Hallum bekräftigt seine Kaufempfehlung	ZM
26.03.	Cerus Corporation gibt FDA-Zulassung für verlängerte Haltbarkeit von INTERCEPT Thrombozyten-Aufbereitungssets bekannt - Verdoppelung der bisherigen Haltbarkeit	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Cerus Corporation to Release First Quarter 2024 Financial Results on May 2, 2024	18.04.
Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets, Doubling Previous Shelf Life	27.03.
Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets – Doubling Previous Shelf Life	26.03.
Cerus Corporation Announces FDA Approval of Extended Shelf Life for INTERCEPT Platelet Processing Sets - Doubling Previous Shelf Life	26.03.
Cerus Says Intercept Blood System Meets Non-Inferiority Goal in Phase 3 Study; Shares Rise	19.03.
Cerus Shares Rise on Positive Results for Intercept Blood Cells Trial	19.03.
Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients	19.03.
Cerus Corporation Announces Positive Topline Results for the Phase 3 Clinical Trial of the INTERCEPT Blood System for Red Blood Cells in Cardiovascular Surgery Patients	19.03.
Cerus Insider Sold Shares Worth $256,377, According to a Recent SEC Filing	15.03.
Cerus: Q4 Earnings Snapshot	05.03.
Cerus Reiterates Full Year 2024 Product Revenue Guidance of $172-$175 Million	05.03.
Earnings Flash (CERS) CERUS CORPORATION Reports Q4 Revenue $53.3M, vs. Street Est of $52M	05.03.
Cerus Corporation Announces Fourth Quarter and Full-Year 2023 Financial Results	05.03.
Cerus Corporation Reiterates Product Revenue Guidance for the Full Year 2024	05.03.
Cerus Corporation Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	05.03.
Microsize Announces Expanded CDMO Relationship with Cerus Corporation	27.02.
Cerus Corporation to Release Fourth Quarter and Full-Year 2023 Financial Results on March 5, 2024	20.02.
Cerus Corporation to Participate in Upcoming Investor Conferences	01.02.
Cerus Corporation Announces Preliminary Fourth Quarter and Full-Year 2023 Product Revenue and Provides Business Update	08.01.
Cerus Corporation Reports Unaudited Preliminary Revenue Results for the Fourth Quarter and Full-Year 2023	08.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Cerus Corporation

Aktien

905249

US1570851014

CERS

Andere Sprachen

Filter